Bone Therapeutics
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more
Bone Therapeutics (0R55) - Total Liabilities
Latest total liabilities as of June 2025: €28.10 Million EUR
Based on the latest financial reports, Bone Therapeutics (0R55) has total liabilities worth €28.10 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bone Therapeutics - Total Liabilities Trend (2011–2024)
This chart illustrates how Bone Therapeutics's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bone Therapeutics Competitors by Total Liabilities
The table below lists competitors of Bone Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Keystone Law Group PLC
LSE:KEYS
|
UK | GBX27.14 Million |
|
CORONATION FD MANAG
BE:N8C
|
Germany | €63.26 Billion |
|
Altitude International Holdings Inc
PINK:ALTD
|
USA | $77.90 Million |
|
Union Financial Corporation
PINK:UFCP
|
USA | $177.17 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Bone Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bone Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bone Therapeutics (2011–2024)
The table below shows the annual total liabilities of Bone Therapeutics from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €31.55 Million | -2.21% |
| 2023-12-31 | €32.26 Million | +23.15% |
| 2022-12-31 | €26.20 Million | -1.27% |
| 2021-12-31 | €26.54 Million | +23.37% |
| 2020-12-31 | €21.51 Million | +5.73% |
| 2019-12-31 | €20.34 Million | -4.31% |
| 2018-12-31 | €21.26 Million | -6.70% |
| 2017-12-31 | €22.79 Million | -2.25% |
| 2016-12-31 | €23.32 Million | +4.85% |
| 2015-12-31 | €22.24 Million | -33.99% |
| 2014-12-31 | €33.69 Million | +164.25% |
| 2013-12-31 | €12.75 Million | +8.22% |
| 2012-12-31 | €11.78 Million | +4.79% |
| 2011-12-31 | €11.24 Million | -- |